Influence of Bifid Triple Viable Capsule on serum endotoxin and inflammatory factor of patients with non-alcoholic steatohepatitis

Objective To discuss the influence of Bifid Triple Viable Capsule on serum endotoxin and inflammatory factor of patients with non-alcoholic steatohepatitis( NASH). Methods 84 cases of patients with NASH were divided into control group and observation group at random. Both groups were given routine liver protection treatment,and the observation group was additionally given 420 mg of Bifid Triple Viable Capsule,twice daily for 4 weeks. The changes of liver function,serum endotoxin,Interleukin-6( IL-6) and tumor necrosis factor-α( TNF-α) levels of patients in boh groups before and after medical treatment were observed. Results After 4 weeks' medical treatment,the ALT,AST and GGT levels of patients in both groups obviously declined( P 0. 05 or P 0. 01),and the declining rate in observation group was much higher than that in control group( P 0. 05). Meanwhile,the serum endotoxin,IL-6 and TNF-α levels of patients in both groups declined obviously than those before treatment( P 0. 05 or P 0. 01),and the declining rate in observation group was much higher than that in control group( P 0. 05). Conclusion Bifid Triple Viable Capsule has favorable adjunctive therapeutic effects on NASH,which can reduce the serum endotoxin,IL-6 and TNF-α levels,reduce intestinal endotoxemia( IETM), inhibit inflammation and immunologic injury of the liver,and improve liver function index.